TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02560805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combat virtual reality video clip
Description: Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
Study: NCT00661583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab and MMC
Description: Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
Study: NCT00619957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: one placebo once a week for two years followed by one 35 mg risedronate once a week for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
Study: NCT04417257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAU-7b
Description: LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Study: NCT01906437

Intervention type: DEVICE
Intervention: Cardiac Magnetic Resonance Scan
Description: Cardiac Magnetic Resonance Scan
Study: NCT03545139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA nusmile
Description: A new formulation of MTA was developed in which bismuth oxide was omitted.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: White MTA
Description: Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
Study: NCT03182738

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VIP app without HIV-related symptom strategies.
Description: The control group will receive the VIP app without HIV-related symptom strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIP app that delivers HIV-related symptom strategies.
Description: The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
Study: NCT01293617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberries
Description: 300 g blackberries daily for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin
Description: 300 g gelatin per day for 5 days
Study: NCT02291211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin HIPEC
Description: Using cisplatin in HIPEC plus oral S-1
Study: NCT03663257

Intervention type: DEVICE
Intervention: AneurysmFlow
Description: AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
Study: NCT00430144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan(CKD-602)
Description: Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Study: NCT04210726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% Hypertonic Saline Bath
Description: 25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Isotonic Saline Bath
Description: 0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
Study: NCT02036229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin cream 0.5%
Description: Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ivermectin cream 0.5%
Description: Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
Study: NCT00083161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60 mg/m2 IV day 1, every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
Study: NCT05383690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED bright light treatment device
Description: Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
Study: NCT03522129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Active Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug
Study: NCT01454076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 2.5 mg
Description: Ixazomib 2.5 mg Capsule B (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 2.5 mg
Description: Ixazomib 2.5 mg Capsule B (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule A
Description: Ixazomib 4 mg Capsule A (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 2 and beyond )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 2 and beyond )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg tablets (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg capsule (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg tablets (Cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 1 and beyond)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 1 and beyond)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg Capsule B
Description: Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
Study: NCT01488006

Intervention type: DEVICE
Intervention: Bigliani/Flatow Shoulder System
Description: Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
Study: NCT03979976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
Study: NCT04186611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early occupational therapy
Description: The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit.
Study: NCT01535235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril 20mg QD x 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD x24wks
Study: NCT02155400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Forced Air Warming Blanket placed over the body of the patient during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype / Experimental device
Description: Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
Study: NCT03778489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: 10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
Study: NCT02343692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided RFA of cystic tumours of the pancreas
Description: Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
Study: NCT04352920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
Study: NCT01339455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AHSCT
Description: AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF
Study: NCT04525729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.

Intervention type: DRUG
Group type: OTHER
Intervention: RAS 2410
Description: To evaluate the efficacy and safety of RASi in patients with IgAN.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS 2410
Description: To evaluate the efficacy and safety of RASi in patients with IgAN.
Study: NCT02122627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Colecalciferol 16.800 IU per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04980131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pointed lotus root regulator and guide template aided PPSF
Description: 20 patients in group C received PPSF with pointed lotus-style regulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flat ended lotus root regulator and guide template aided PPSF
Description: 20 patients in group B received PPSF with flat ended lotus-style regulator
Study: NCT02560805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combat virtual reality video clip
Description: Subjects will watch a video clip of combat on a computer screen or wearing video goggles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handgrip Exercise
Description: Subjects will squeeze a hand dynamometer intermittently.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handgrip Exercise
Description: Subjects will squeeze a hand dynamometer intermittently.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Description: Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Description: Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Description: Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Description: Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Subjects will receive Losartan 25 mg once a day orally up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
Study: NCT02665117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Magnesium Citrate (KMgCit)
Description: KMgCit will be administer for 4 months with chlorthalidone.
Study: NCT03501056

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT04433117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shefabone
Description: Silica-calcium phosphate composite.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bio-Oss
Description: Xenograft Bone substitute. Bone from animals.
Study: NCT03360812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training resource
Description: Please see information included in the description of the intervention group.
Study: NCT04219436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical mattress suturing technique
Description: vertical mattress suturing technique used for flap closure after esthetic crown lengthening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: figure of eight suturing technique
Description: figure of eight suturing technique used for flap closure after esthetic crown lengthening
Study: NCT01118910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vusion
Description: Vusion will be applied to areas of intertrigo
Study: NCT00227357

Intervention type: DRUG
Intervention: On-site - buprenorphine/naloxone (Suboxone)
Description: Tablet, sub-lingual, 8/2 mg, 1-3 daily

Intervention type: DRUG
Intervention: Off-site - methadone or no agonist
Study: NCT02610985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-D laparoscopy
Description: 3-D laparoscopy
Study: NCT02665117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride (KCl)
Description: KCl will be administer for 4 months with chlorthalidone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
Study: NCT02610985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-D laparoscopy
Description: 2-D laparoscopy
Study: NCT02893345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe@Home Intervention Group
Description: For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
Study: NCT01524380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba extract
Description: 400mg/day, twice a day, 10 weeks
Study: NCT03127059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
Study: NCT03476642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
Study: NCT01524380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day, 10 weeks
Study: NCT02953041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: long-acting muscarinic antagonist
Study: NCT01190930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02953041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: long-acting muscarinic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: ultra long-acting beta agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: ultra long-acting beta agonist
Study: NCT01413386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: palliative treatment for malignant patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent
Description: palliative treatment for malignant patients
Study: NCT03227874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried apple
Description: diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried apple
Description: diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muffin
Description: two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muffin
Description: two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
Study: NCT04003610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5 mg once a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5 mg once a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle